Xeris Biopharma Holdings, Inc.
XERS
$5.97
-$0.11-1.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 38.27% | 42.78% | 37.06% | 48.84% | 47.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.27% | 42.78% | 37.06% | 48.84% | 47.94% |
| Cost of Revenue | 21.15% | 15.50% | -19.11% | 52.73% | 46.17% |
| Gross Profit | 41.18% | 47.88% | 55.83% | 48.08% | 48.24% |
| SG&A Expenses | 20.73% | 18.34% | 3.31% | 11.00% | 14.69% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.04% | -0.04% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.99% | 18.17% | 0.73% | 19.21% | 15.17% |
| Operating Income | 356.18% | 898.99% | 152.21% | 154.75% | 78.31% |
| Income Before Tax | 124.23% | 316.72% | 103.26% | 86.48% | 50.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 124.23% | 316.72% | 103.95% | 87.15% | 51.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 124.23% | 316.72% | 103.95% | 87.15% | 51.42% |
| EBIT | 356.18% | 898.99% | 152.21% | 154.75% | 78.31% |
| EBITDA | 16,966.15% | 321.41% | 199.04% | 244.69% | 99.42% |
| EPS Basic | 121.65% | 294.75% | 103.60% | 88.03% | 55.22% |
| Normalized Basic EPS | 121.69% | 294.86% | 102.94% | 87.86% | 56.10% |
| EPS Diluted | 116.53% | 288.63% | 103.18% | 88.03% | 55.22% |
| Normalized Diluted EPS | 120.90% | 279.91% | 102.69% | 87.86% | 56.10% |
| Average Basic Shares Outstanding | 11.86% | 11.31% | 9.84% | 7.49% | 8.49% |
| Average Diluted Shares Outstanding | 16.52% | 20.78% | 19.21% | 7.49% | 8.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |